AstraZeneca and Saint Luke ’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients
AstraZeneca and Saint Luke's Mid America Heart Institute have initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a treatment in patients hospitalised with COVID-19 who are at risk of developing serious complications, such as organ failure. (Source: World Pharma News)
Source: World Pharma News - April 23, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Diabetes Drug Slows Kidney Disease: DAPA-CKD Trial Stopped Early Diabetes Drug Slows Kidney Disease: DAPA-CKD Trial Stopped Early
AstraZeneca has announced that the phase 3 DAPA-CKD trial for dapagliflozin (Farxiga) in patients with chronic kidney disease has been halted early because of overwhelming efficacy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 31, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Dapagliflozin Granted Priority Review for Adults With Heart Failure Dapagliflozin Granted Priority Review for Adults With Heart Failure
The application for the SGLT2 inhibitor is based on the results from the landmark phase 3 DAPA-HF trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 8, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction
AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type-2 diabetes (T2D). (Source: World Pharma News)
Source: World Pharma News - January 6, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
AHA Names Top Heart Disease, Stroke Research Advances of 2019 AHA Names Top Heart Disease, Stroke Research Advances of 2019
A watch that detects atrial fibrillation, prescription fish oil for CV risk reduction, and the promise of dapagliflozin in HF are among the major advances for 2019, says the American Heart Association.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 2, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
Dec 6, 2019 This Week in Cardiology Dec 6, 2019 This Week in Cardiology
Vernakalent, CV death in cancer patients, dapagliflozin, and sacubitril/valsartan are the topics Dr. John Mandrola discusses in this week ' s podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 6, 2019 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
Making Room for New Drugs for Heart Failure Making Room for New Drugs for Heart Failure
Drs Ileana Pi ñ a and Mary Walsh discuss the latest HF updates from the American Heart Association Scientific Sessions and ask where dapagliflozin and sacubitril/valsartan will fit in the armamentarium.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 26, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news
DAPA-HF: Dapagliflozin Benefits Regardless of Age, HF Severity DAPA-HF: Dapagliflozin Benefits Regardless of Age, HF Severity
The SGLT2 inhibitor showed about the same effect on its clinical primary end point in the very elderly and across all degrees of symptom status at baseline in two new analyses.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 25, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
FDA OKs Diabetes Drug for Type 2 Heart Failure Risk
The FDA granted a new use for diabetes drug Farxiga (dapagliflozin): to reduce the risk of hospitalization for heart failure in adults who have type 2 diabetes and established heart disease or risk factors for it. (Source: WebMD Health)
Source: WebMD Health - October 22, 2019 Category: Consumer Health News Source Type: news
FDA OKs Dapagliflozin to Reduce HF Hospitalization in Diabetes FDA OKs Dapagliflozin to Reduce HF Hospitalization in Diabetes
Dapagliflozin (Farxiga, AstraZeneca) has additionally been approved in the US for reducing hospitalization for heart failure (HF) in adults with type 2 diabetes and other cardiovascular risk factors.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 21, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news
FDA Approves Farxiga (dapagliflozin) to Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes
21 October 2019 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure (hHF) in adults with type 2 diabetes (T2D) and established... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 21, 2019 Category: Drugs & Pharmacology Source Type: news
What Do You Think of Dapagliflozin for Heart Failure? What Do You Think of Dapagliflozin for Heart Failure?
Recent trial results indicate that the diabetes drug provides substantial benefits for heart failure patients, even those without diabetes.Medscape Reader Polls (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 2, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Dapagliflozin Lowers Risk for Worsening Heart Failure
MONDAY, Sept. 23, 2019 -- For patients with heart failure and reduced ejection fraction, dapagliflozin is associated with a lower risk for worsening heart failure or death from cardiovascular causes, regardless of the presence of type 2 diabetes,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 23, 2019 Category: Pharmaceuticals Source Type: news
EU Panel Votes to Expand Dulaglutide Indication Based on REWIND EU Panel Votes to Expand Dulaglutide Indication Based on REWIND
The panel also recommends approval of Qtrilmet, a fixed-dose combination of metformin hydrochloride/saxagliptin/dapagliflozin for treatment of type 2 diabetes.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 20, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
Sep 20 2019 This Week in Cardiology Sep 20 2019 This Week in Cardiology
The polypill, dapagliflozin, TAVR, and video games are discussed by John Mandrola, MD, in this week ’ s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 20, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news
